Peptides are derived from animal source and possess antibacterial activity that comes under animal antibacterial peptides. They contain residue of amino acids generally about 15 to 45. Antibacterial peptides are the effector molecules of innate immunity. Majority of the antibacterial peptides are cationic in nature. In insects, the cecropin type of linear peptide without cysteine are found. Now, more than 900 sequences of proteins and antibacterial peptides from plants and animals are stored in database. The antibacterial peptides are broad spectrum in activity. The antibacterial peptides are amphipathic in structure and contains positive charge.
The use of low levels of antibiotics in animal feed as growth promoters and rise in use of antibiotics in animal and human infections are causes of antibiotics resistance among gram negative, gram positive, and bacterial pathogens. The natural and synthetics antibacterial peptides are good candidates for antibiotics alternatives. The natural antibiotics are rich source of proteins as well as amino acids and have less side effects as compared to synthetic antibiotics. They possess synergistic activity with conventional antibiotics and promote wound healing. Domestic animals are good source of antibacterial peptides. The antibacterial peptides are expressed in many polymorphonuclear leukocytes, tissues, macrophages, and mucosal epithelial cells. Antibacterial peptides are preserved in their function, structure, and mechanisms of action. Thus, it is attractive to speculate that synthetic antibacterial peptides or their congeners might be used to prevent or treat infections. Antimicrobial peptides are good applicants for the design of new antimicrobial agents for specific application because of their low propensity for the development of bacterial resistance and natural antimicrobial properties. The major driving factor of antibacterial peptides is their ability to kill multi drug resistance bacteria.
The market of animal antibacterial peptide is segmented on the basis of peptide type, product origin, and geography. On the basis of peptide type, the animal antibacterial peptide market is segmented as linear cationic α-helical peptides, anionic peptides, cationic peptide containing specific amino acid, and anionic & cationic peptides that possess cysteine and form disulfide bonds. Anionic peptides are rich in glutamic and aspartic acids whereas cationic peptides are rich in arginine, phenylalanine, glycine, tryptophan, and proline. These peptides are good candidates for supplements to conventional antibiotic therapy and for development as novel therapeutic agents. These are broad spectrum in nature and possess bactericidal activity. Insect’s peptides are one of the largest groups of antimicrobial peptides. Cecropins constitute the most important host defense system against bacterial infection. By product origin, the animal antibacterial peptide market is segmented into cattle origin, sheep origin, goat origin, pig origin, horse origin, and poultry. The animal antibacterial peptides are derived from above sources.
By geography, the market for animal antibacterial peptide is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are expected to dominate the market. The rise in research is the key driving factor of the animal antibacterial peptide market in North America. Asia pacific is the most progressive region for the animal antibacterial peptide market. The rise in expenditure on animal health care is a key factor responsible for growth of the market. The increasing resistance to conventional antibiotics is likely to be the key driver of the animal antibacterial peptide market during the forecast period. Furthermore, the rise in use of antibiotics to treat various infections and disease in animal feed is projected to fuel the growth of the animal antibacterial peptide market during the forecast period.
Major players operating in the animal antibacterial peptide market include Zoetis, Merck Animal Health, Merial, Elanco (Eli Lilly and Company), Bayer HealthCare, Animal Medics, Biogenesis Bago, and Boehringer Ingelheim Vetmedica. The rising demand for alternatives for conventional antibiotics is estimated to increase the competition between market players of animal antibacterial peptide.
Note : All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Transparency Market Research.